ovarian adnexal mass
Aspira Q4 Revenues up 36 Percent
The company reported total revenues of $1.9 million, up from $1.4 million in Q4 2020, while sales of its OVA1plus test were up 23 percent.
Aspira Women's Health Preliminary Q4 OVA1 Sales up 23 Percent; Firm Details Pipeline Progess
The company also announced a five-year deal with healthcare group Axia Women's Health to provide in-house genetic carrier screening.
Aspira Women's Health Q3 Revenues Up 34 Percent
The cancer diagnostics firm posted $1.7 million in revenues, up from $1.2 million the year prior, and completed 4,281 OVA ovarian cancer tests.
Aspira Q2 Revenues More Than Double
The company reported total revenues of $1.8 million, up from $746,000 a year ago, and posted sales of 4,553 OVA1plus tests, up from 2,458 in Q2 2020.
The company is developing tests for ovarian mass monitoring and endometriosis that it hopes will expand its addressable market beyond that targeted by OVA1.